Free Trial

Beam Therapeutics (BEAM) News Today

Beam Therapeutics logo
$16.32 -0.56 (-3.32%)
Closing price 04:00 PM Eastern
Extended Trading
$16.58 +0.26 (+1.60%)
As of 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BEAM Latest News

Beam Therapeutics Inc. stock logo
Polar Asset Management Partners Inc. Has $5.17 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Polar Asset Management Partners Inc. lifted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 901.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 208,255 shares of the company
Beam Therapeutics Inc. stock logo
Squarepoint Ops LLC Invests $3.85 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)
Squarepoint Ops LLC bought a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 155,278 shares of the company's stock, valued at approximately $3,851,000. Squarepoint Op
Beam Therapeutics Inc. stock logo
Voloridge Investment Management LLC Has $10.25 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)
Voloridge Investment Management LLC reduced its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 413,409 shares of the company's stock after selling 50,253
Beam Therapeutics Inc. stock logo
Woodline Partners LP Takes Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Woodline Partners LP purchased a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 282,120 shares of the company's stock, valu
Beam Therapeutics Inc. stock logo
Deutsche Bank AG Has $1.67 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Deutsche Bank AG grew its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 54.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,508 shares of the company's stock after purchasing an additional 23,871 shares during
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from Analysts
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been assigned an average rating of "Buy" from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have a
Beam Therapeutics Inc. stock logo
Twinbeech Capital LP Purchases 69,456 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Twinbeech Capital LP boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 119.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,664 shares of the company's stock after buyin
Beam Therapeutics Inc. stock logo
Rafferty Asset Management LLC Has $2.76 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Rafferty Asset Management LLC lowered its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 40.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,100 shares of the company's stock after selli
Beam Therapeutics Inc. stock logo
Point72 Asset Management L.P. Buys Shares of 193,356 Beam Therapeutics Inc. (NASDAQ:BEAM)
Point72 Asset Management L.P. bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 193,356 shares of the company's stock, valued a
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Tang Capital Management LLC
Tang Capital Management LLC lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 70.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the company's stock after selling 120,00
Beam Therapeutics Inc. stock logo
Raiffeisen Bank International AG Invests $1.26 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)
Raiffeisen Bank International AG purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company's stock, val
Beam Therapeutics Inc. stock logo
Polar Asset Management Partners Inc. Acquires 187,455 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Polar Asset Management Partners Inc. increased its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 901.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,255 shares of the company's stock after acqui
Beam Therapeutics Inc. stock logo
Hudson Bay Capital Management LP Sells 15,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Hudson Bay Capital Management LP cut its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 13.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the company's stock after selling 15
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp
Northern Trust Corp boosted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 7.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 740,506 shares of the company's stock after acquiring an additional 49,415 shares during the peri
Beam Therapeutics Inc. stock logo
Algert Global LLC Has $233,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Algert Global LLC reduced its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 78.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,378 shares of the company's stock after sell
Beam Therapeutics Inc. stock logo
HC Wainwright Issues Positive Forecast for BEAM Earnings
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for Beam Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($
Beam Therapeutics Inc. stock logo
Leerink Partnrs Issues Optimistic Forecast for BEAM Earnings
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for Beam Therapeutics in a note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will p
Beam Therapeutics Inc. stock logo
Q2 EPS Forecast for Beam Therapeutics Reduced by Analyst
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair cut their Q2 2025 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, May 6th. William Blair analyst S. Corwin now expects that the company will post earnings of ($1.01)
Beam Therapeutics Inc. stock logo
Farallon Capital Management LLC Purchases 31,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Farallon Capital Management LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 0.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,239,123 shares of the company's stock after acquiring an a
Beam Therapeutics Inc. stock logo
Crestline Management LP Increases Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Crestline Management LP grew its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 261.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,969 shares of the company's st
Beam Therapeutics Inc. stock logo
Tudor Investment Corp ET AL Sells 16,242 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Tudor Investment Corp ET AL trimmed its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 49.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,575 shares
Beam Therapeutics Inc. stock logo
Q2 Earnings Estimate for Beam Therapeutics Issued By Wedbush
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Research analysts at Wedbush cut their Q2 2025 earnings estimates for Beam Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now anticipates that the company will post earning
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company
Wells Fargo & Company lowered their target price on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday.
Beam Therapeutics Inc. stock logo
Barclays Lowers Beam Therapeutics (NASDAQ:BEAM) Price Target to $25.00
Barclays reduced their price target on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a research report on Wednesday.
Beam Therapeutics Inc. stock logo
Raymond James Financial Inc. Takes $703,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
Raymond James Financial Inc. bought a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 28,328 shares of the company's stock, valued at approximately $703,000. Several other
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Shares Down 6.8% on Disappointing Earnings
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.8% Following Weak Earnings
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Stock Holdings Raised by Casdin Capital LLC
Casdin Capital LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 61.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,250,000 shares of the company's stock after purchasing an additional 475,000 shares during
Beam Therapeutics Inc. stock logo
Dimensional Fund Advisors LP Has $38.16 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)
Dimensional Fund Advisors LP lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 24.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,538,398 shares of the company's stock af
Beam Therapeutics Inc. stock logo
Renaissance Technologies LLC Makes New $568,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)
Renaissance Technologies LLC purchased a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 22,907 shares of the company's stock, valued at approxi
Beam Therapeutics Inc. stock logo
ARCH Venture Management LLC Sells 294,521 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
ARCH Venture Management LLC lessened its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,540,132 shares of the company's stock after selling 2
Beam Therapeutics Inc. stock logo
Susquehanna Fundamental Investments LLC Acquires New Shares in Beam Therapeutics Inc. (NASDAQ:BEAM)
Susquehanna Fundamental Investments LLC acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 52,725 shares of the company's stock, val
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Update
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 18,830,000 shares, an increase of 27.7% from the March 31st total of 14,740,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the short-interest ratio is currently 8.9 days. Approximately 23.7% of the company's shares are sold short.
Beam Therapeutics Inc. stock logo
Price T Rowe Associates Inc. MD Purchases 266,834 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Price T Rowe Associates Inc. MD raised its position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,753,142 shares of the company's stock after purchasing an
Beam Therapeutics Inc. stock logo
Beam Therapeutics (BEAM) Projected to Post Quarterly Earnings on Tuesday
Beam Therapeutics (NASDAQ:BEAM) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-beam-therapeutics-inc-stock/)
Beam Therapeutics Inc. stock logo
Marshall Wace LLP Buys Shares of 55,000 Beam Therapeutics Inc. (NASDAQ:BEAM)
Marshall Wace LLP bought a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 55,000 shares of the company's stock, valued at approximately $1,364,000. Marshall Wace LLP owned 0.07% of Be
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Buy" from Brokerages
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received an average recommendation of "Buy" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and t
Beam Therapeutics Inc. stock logo
Barclays PLC Increases Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Barclays PLC boosted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 51.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 278,019 shares of the company's stock after buying an additional 94,805 shares during
Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

BEAM Media Mentions By Week

BEAM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BEAM
News Sentiment

1.48

0.87

Average
Medical
News Sentiment

BEAM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BEAM Articles
This Week

10

7

BEAM Articles
Average Week

Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BEAM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners